We have located links that may give you full text access.
Synthesis, preclinical, and initial clinical evaluation of integrin α V β 3 and gastrin-releasing peptide receptor (GRPR) dual-targeting radiotracer [ 68 Ga]Ga-RGD-RM26-03.
European Journal of Nuclear Medicine and Molecular Imaging 2024 Februrary 21
UNLABELLED: Integrin receptor αv β3 and gastrin-releasing peptide receptor (GRPR) expression of tumors could be detected using PET imaging with radiolabeled Arg-Gly-Asp (RGD) and the antagonistic bombesin analog RM26, respectively. The purpose of this study was to investigate the dual receptor-targeting property of the heterodimer RGD-RM26-03 (denoted as LNC1015), demonstrate the tumor diagnostic value of [68 Ga]Ga-LNC1015 in preclinical experiments, and evaluate its preliminary clinical feasibility.
METHODS: LNC1015 was designed and synthesized by linking cyclic RGD and the RM26 peptide. Preclinical pharmacokinetics were detected in a PC3 xenograft model using microPET and biodistribution studies. The clinical feasibility of [68 Ga]Ga-LNC1015 PET/CT was performed in patients with breast cancer, and the results were compared with those of 18 F-fluorodeoxyglucose (FDG).
RESULTS: [68 Ga]Ga-LNC1015 had good stability in saline for at least 2 h, and favorable binding affinity and specificity were demonstrated in vitro and in vivo. The tumor uptake and retention of [68 Ga]Ga-LNC1015 during PET imaging were improved compared with its monomeric counterparts [68 Ga]Ga-RGD and [68 Ga]Ga-RM26 at all the time points examined. In our initial clinical studies, the tumor uptake and tumor-to-background ratio (TBR) of primary and metastatic lesions in [68 Ga]Ga-LNC1015 PET/CT were significantly higher than those in [18 F]FDG PET/CT, resulting in high lesion detection rate and tumor delineation.
CONCLUSION: The dual targeting radiotracer [68 Ga]Ga-LNC1015 showed significantly improved tumor uptake and retention, as well as lower liver uptake than [68 Ga]Ga-RGD and [68 Ga]Ga-RM26 monomer. The first-in-human study showed high TBRs in patients, suggesting favorable pharmacokinetics and high clinical feasibility for PET/CT imaging of cancer.
METHODS: LNC1015 was designed and synthesized by linking cyclic RGD and the RM26 peptide. Preclinical pharmacokinetics were detected in a PC3 xenograft model using microPET and biodistribution studies. The clinical feasibility of [68 Ga]Ga-LNC1015 PET/CT was performed in patients with breast cancer, and the results were compared with those of 18 F-fluorodeoxyglucose (FDG).
RESULTS: [68 Ga]Ga-LNC1015 had good stability in saline for at least 2 h, and favorable binding affinity and specificity were demonstrated in vitro and in vivo. The tumor uptake and retention of [68 Ga]Ga-LNC1015 during PET imaging were improved compared with its monomeric counterparts [68 Ga]Ga-RGD and [68 Ga]Ga-RM26 at all the time points examined. In our initial clinical studies, the tumor uptake and tumor-to-background ratio (TBR) of primary and metastatic lesions in [68 Ga]Ga-LNC1015 PET/CT were significantly higher than those in [18 F]FDG PET/CT, resulting in high lesion detection rate and tumor delineation.
CONCLUSION: The dual targeting radiotracer [68 Ga]Ga-LNC1015 showed significantly improved tumor uptake and retention, as well as lower liver uptake than [68 Ga]Ga-RGD and [68 Ga]Ga-RM26 monomer. The first-in-human study showed high TBRs in patients, suggesting favorable pharmacokinetics and high clinical feasibility for PET/CT imaging of cancer.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app